|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 5
Zeitschriftenartikel
Krüger, S.; Heinemann, V.; Ross, C.; Diehl, F.; Nagel, D.; Ormanns, S.; Liebmann, S.; Prinz-Bravin, I.; Westphalen, C. B.; Haas, M.; Jung, A.; Kirchner, T.; Bergwelt-Baildon, M. von; Böck, S. und Holdenrieder, S.
(2018):
Repeated (mut)KRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer.
In: Annals of Oncology, Bd. 29, Nr. 12: S. 2348-2355
Zeiss, K.; Parhofer, K. G.; Heinemann, V.; Haas, M.; Laubender, Rüdiger P.; Holdenrieder, S.; Schulz, C. und Boeck, S.
(2013):
Glucose and lipid metabolism in patients with advanced pancreatic cancer receiving palliative chemotherapy.
In: Anticancer Research, Bd. 33, Nr. 1: S. 287-292
Haas, M.; Heinemann, V.; Kullmann, F.; Laubender, Rüdiger P.; Klose, C.; Bruns, C. J.; Holdenrieder, S.; Modest, D. P.; Schulz, C. und Boeck, S.
(2013):
Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.
In: Journal of Cancer Research and Clinical Oncology, Bd. 139, Nr. 4: S. 681-689
Boeck, S.; Haas, M.; Laubender, Rüdiger P.; Kullmann, F.; Klose, C.; Bruns, C. J.; Wilkowski, R.; Stieber, P.; Holdenrieder, S.; Buchner, Hannes; Mansmann, Ulrich und Heinemann, V.
(2010):
Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer.
In: Clinical Cancer Research, Bd. 16, Nr. 3: S. 986-994
Haas, M.; Laubender, Rüdiger P.; Stieber, P.; Holdenrieder, S.; Bruns, C. J.; Wilkowski, R.; Mansmann, Ulrich; Heinemann, V. und Boeck, S.
(2010):
Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer.
In: Tumor Biology, Bd. 31, Nr. 4: S. 351-357